Ardelyx to Participate in Several Upcoming Investor Conferences

WALTHAM, Mass., Sept. 01, 2026 /CourierPR/ -- Ardelyx, a biopharmaceutical company, is set to participate in several upcoming investor conferences, providing updates on its products and pipeline.

The company will be present at Citi's 2026 Biopharma Back to School Conference, held in New York, New York, on September 9. Ardelyx will also attend the 2026 Cantor Global Healthcare Conference, where it will host a fireside chat on September 10 at 11:30 AM Eastern Time and conduct investor meetings. Additionally, Ardelyx will be part of the Morgan Stanley 24th Annual Global Healthcare Conference, participating in a fireside chat on September 16 at 7:45 AM ET, followed by investor meetings.

Attendees can access live webcasts of the fireside chats by visiting the Events and Presentations page on Ardelyx’s website at ir.ardelyx.com. Replay options will be available post-event.

Ardelyx focuses on developing and commercializing innovative medicines to address significant unmet medical needs. The company currently markets two products in the United States: IBSRELA® (tenapanor) and XPHOZAH® (tenapanor). Currently in Phase 3 development, IBSRELA is being evaluated for chronic idiopathic constipation (CIC). Ardelyx also has RDX10531, a next-generation NHE3 inhibitor, in its pipeline, with potential applications in multiple therapeutic areas.